US FDA Approves Exdensur (depemokimab) for Severe Asthma Treatment
TL;DR Summary
GSK's Exdensur (depemokimab) has been approved by the US FDA as a twice-yearly treatment for severe eosinophilic asthma in patients aged 12 and older, based on phase III trial data showing significant reduction in exacerbations and hospitalizations, with a favorable safety profile.
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
6 min
vs 6 min read
Condensed
96%
1,180 → 42 words
Want the full story? Read the original article
Read on GSK